Nicholas W Lange

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8387916/publications.pdf

Version: 2024-02-01

		1307594	1058476	
15	251	7	14	
papers	citations	h-index	g-index	
15	15	15	199	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Comparing weightâ€based dosing of tacrolimus XR in obese and nonâ€obese renal transplant recipients. Clinical Transplantation, 2022, 36, e14529.	1.6	4
2	Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. Clinical Transplantation, 2022, 36, e14594.	1.6	11
3	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. American Journal of Transplantation, 2022, 22, 1925-1926.	4.7	54
4	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 2083-2088.	4.7	64
5	Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients. Transplant Infectious Disease, 2022, 24, .	1.7	1
6	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. American Journal of Transplantation, 2022, 22, 2682-2688.	4.7	35
7	Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. Journal of Intensive Care Medicine, 2021, 36, 524-541.	2.8	11
8	Deceased donor renal transplantation in patients on apixaban at time of transplant surgery: A case series. Clinical Transplantation, 2021, 35, e14148.	1.6	1
9	Managing the significant drugâ€drug interaction between tacrolimus and letermovir in solid organ transplant recipients. Clinical Transplantation, 2021, 35, e14213.	1.6	6
10	Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. Clinical Transplantation, 2021, 35, .	1.6	6
11	An evaluation of PJP prophylaxis and anemia among renal transplant recipients. Transplant Infectious Disease, 2020, 23, e13543.	1.7	2
12	ManagingÂthe significantÂinteraction between XR tacrolimus and fluconazole in kidney transplant recipients. Clinical Transplantation, 2020, 34, e14001.	1.6	1
13	Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. International Journal of Cardiology, 2018, 265, 71-76.	1.7	32
14	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. Clinical Transplantation, 2018, 32, e13415.	1.6	16
15	Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations. Clinical Transplantation, 2017, 31, e13098.	1.6	7